Published in Adv Drug Deliv Rev on November 12, 2009
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine (2010) 1.04
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem (2014) 0.94
Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomedicine (2012) 0.88
From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov (2015) 0.85
Nanotechnology and the treatment of HIV infection. Viruses (2012) 0.84
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release (2015) 0.83
Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability. Biomed Res Int (2017) 0.83
Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomedicine (2014) 0.81
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. J Nanobiotechnology (2011) 0.80
Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets. Viruses (2014) 0.79
Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages. Int J Nanomedicine (2015) 0.77
The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond) (2015) 0.76
Microbicides for the Treatment of Sexually Transmitted HIV Infections. J Pharm (Cairo) (2014) 0.76
Stelleralides D-J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme. J Nat Prod (2015) 0.75
Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes. J Pers Nanomed (2015) 0.75
An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. Parasitol Res (2016) 0.75
Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today (2007) 2.50
Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev (2008) 1.80
Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res (2007) 1.77
Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv (2006) 1.61
Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm (2002) 1.37
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res (2007) 1.34
Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm (2005) 1.30
Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol (2008) 1.25
Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release (2005) 1.22
Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine (2007) 1.21
A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv (2006) 1.20
Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials (2013) 1.20
Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One (2010) 1.16
Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J Control Release (2003) 1.15
Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release (2007) 1.12
Nanoparticle-based endodontic antimicrobial photodynamic therapy. J Endod (2009) 1.12
Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res (2008) 1.12
In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release (2013) 1.11
Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv (2007) 1.08
Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm (2007) 1.08
Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer (2009) 1.05
Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer (2007) 1.04
Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev (2013) 1.03
Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer. Mol Ther Nucleic Acids (2013) 1.03
Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res (2006) 0.99
Role of nanotechnology in pharmaceutical product development. J Pharm Sci (2007) 0.99
Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol (2006) 0.95
Mucoadhesive nanosystems for vaginal microbicide development: friend or foe? Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.95
Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv (2006) 0.94
Rheological properties of vaginal hydrophilic polymer gels. Curr Drug Deliv (2009) 0.94
Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech (2014) 0.92
Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J (2010) 0.91
Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat (2005) 0.91
Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin Drug Deliv (2011) 0.89
Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech (2008) 0.89
Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis. Biomed Eng Online (2010) 0.88
Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul (2007) 0.88
Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm (2008) 0.88
Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Pharm Res (2014) 0.88
Anti-angiogenic and anti-cancer evaluation of betulin nanoemulsion in chicken chorioallantoic membrane and skin carcinoma in Balb/c mice. J Biomed Nanotechnol (2013) 0.86
Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles. AAPS PharmSci (2003) 0.86
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev (2013) 0.86
Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res (2011) 0.86
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv (2009) 0.85
Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin Orthop Relat Res (2013) 0.85
Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm (2012) 0.85
Safety assessment of oral photodynamic therapy in rats. Lasers Med Sci (2012) 0.85
Oral insulin delivery: how far are we? J Diabetes Sci Technol (2013) 0.84
Smart stimuli sensitive nanogels in cancer drug delivery and imaging: a review. Curr Pharm Des (2013) 0.84
Novel non-invasive methods of insulin delivery. Expert Opin Drug Deliv (2012) 0.84
Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles. J Pharm Biomed Anal (2010) 0.84
Performance of an in vitro mucoadhesion testing method for vaginal semisolids: influence of different testing conditions and instrumental parameters. Eur J Pharm Biopharm (2008) 0.84
Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model. Mol Pharm (2014) 0.84
The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance. J Pharm Sci (2015) 0.83
Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance. Curr Med Chem (2015) 0.83
Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci (2010) 0.83
How to overcome the limitations of current insulin administration with new non-invasive delivery systems. Ther Deliv (2015) 0.83
In vitro and in vivo studies of local arterial gene delivery and transfection using lipopolyplexes-embedded stents. J Biomed Mater Res A (2010) 0.82
The importance of antimicrobial peptides and their potential for therapeutic use in ophthalmology. Int J Antimicrob Agents (2012) 0.82
Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying. Biomatter (2013) 0.82
A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells. Biotechnol Bioeng (2008) 0.82
Photodynamic effects of methylene blue-loaded polymeric nanoparticles on dental plaque bacteria. Lasers Surg Med (2011) 0.82
Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym (2013) 0.81
Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications. Org Biomol Chem (2015) 0.81
Synthesis and evaluation of tripodal peptide analogues for cellular delivery of phosphopeptides. J Med Chem (2007) 0.81
Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol (2012) 0.81
Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine (Lond) (2011) 0.81
Validation of a high-performance liquid chromatography method for the determination of (-)-alpha-bisabolol from particulate systems. Biomed Chromatogr (2009) 0.81
Models to predict intestinal absorption of therapeutic peptides and proteins. Curr Drug Metab (2013) 0.81
Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res (2014) 0.81
Assessing the physical-chemical properties and stability of dapivirine-loaded polymeric nanoparticles. Int J Pharm (2013) 0.81
Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv Transl Res (2011) 0.80
Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm (2011) 0.80
Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.80
Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. Pharm Res (2014) 0.79
Interactions of microbicide nanoparticles with a simulated vaginal fluid. Mol Pharm (2012) 0.79
'Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics. Bioorg Med Chem (2011) 0.79
Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? J Diabetes Sci Technol (2012) 0.79
Synthesis and preliminary in vivo evaluations of polyurethane microstructures for transdermal drug delivery. Chem Cent J (2012) 0.79
In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine. Mol Pharm (2013) 0.79
Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm (2013) 0.79
Targeted delivery systems for biological therapies of inflammatory diseases. Expert Opin Drug Deliv (2014) 0.79
Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease. Clin Transl Gastroenterol (2011) 0.79
Chitosan-based nanoparticles as delivery systems of therapeutic proteins. Methods Mol Biol (2012) 0.79
Development and validation of a simple reversed-phase HPLC method for the determination of camptothecin in animal organs following administration in solid lipid nanoparticles. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.79
The impact of size on particulate vaccine adjuvants. Nanomedicine (Lond) (2014) 0.79
Preparation and loading of gelatin nanoparticles. CSH Protoc (2008) 0.78
CNS delivery and pharmacokinetic evaluations of DALDA analgesic peptide analog administered in Nano-sized oil-in-water emulsion formulation. Pharm Res (2013) 0.78
Nanoparticles: a promising modality in the treatment of sarcomas. Pharm Res (2010) 0.78